

Best Available Copy

.10 | 3 | 03.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it is a
number. Complete if Known.

Approved for use through 10/31/2024

TO/SB/08 (08-00)
12. OMB 0651-0031
U.S. DEPT. OF COMMERCE
OMB control

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	Unassigned 10/6
Date Submitted: October 3, 2003		Filing Date	10/03/2003
(use as many sheets as necessary)		First Named Inventor	Hiroaki ITO et al.
Sheet	4	Group Art Unit	1646
		Examiner Name	Unassigned Preu
		Attorney Docket Number	05346E-0365

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document(s)	Date of Publication of Cited Document MM-DD-YYYY	Page
		Office ³	Number ⁴			
PM	A1	WO	96/40966	A1 Private Biologicals Corporation	12/19/1996	1
	A2	JP	7-324097		12/24/1995	2
	A3	JP	8-311098		11/26/1996	3
	A4	JP	8-245414		09/24/1996	4
	A5	JP	9-235276		09/09/1997	5
	A6	JP	8-99996		04/18/1996	6
	A7	JP	8-50829		09/03/1996	7
	A8	WO	96/40966	WO 96/40966	12/19/1996	8
	A9	WO	96/38481	The Board of Regents of the University of Oklahoma	12/05/1996	9
	A10	EP	0 811 384	SEIYAKU et al.	12/10/1997	10
	A11	WO	99/64069	Ophidian Pharmaceuticals Inc.	12/16/1999	11

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-is-# number(s). publisher, city and/or country where published.			
PM	A12	POWRIE et al., "Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease In scid Mice Reconstituted With CD45Rbhi CD4+ T Cells", <i>Immunity</i> , Vol. 1:553-562, (1994).			T#
	A13	TAKAGI et al., "Blockage Of Interleukin-6 Receptor Ameliorates Joint Disease In Murine Collagen-Induced Arthritis", <i>Arthritis Rheumatism</i> , Vol. 41(12):2117-2121, (1998).			
	A14	MITSUYAMA et al., "Soluble Interleukin-6 Receptors In Inflammatory Bowel Disease; Relation To Circulating Interleukin-6", <i>Gut</i> , Vol. 36:45-49, (1995).			
	A15	VAN DULLEMEN et al., "Treatment Of Crohn's Disease With Anti-Tumor Necrosis Factor Monoclonal Antibody (cA2)", <i>Gastroenterology</i> , Vol. 109:129-135, (1995).			
	A16	SASAJIMA et al., "Changes in Serum Cytokine Profile During Treatment of Ulcerative Colitis", <i>Journal of Gastroenterology and Hepatology</i> , December 1997, page A274, vol. 12, no. SUPPL., XP#01105732.			

Examiner Signature	Premia Meek	Date Considered	7/24/06
--------------------	-------------	-----------------	---------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Entering Office that issued the document, by the name Standard ST 1. ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number. ⁵ Standard ST 1. ⁶ If possible. ⁷ Applicant is to

^bKind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.3 if possible. Applicant is to attach English language Translation if attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual.
The amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20591-0000, or to the Assistant Commissioner for Patents, Washington, DC 20591-0000.

The amount of time you are required to complete this form should be set as of January 1, 2023. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C.

letter code (WIPO
the patent document
ice a check mark here if

case. Any comments on

case. Any comments on
the Washington, D.C.
area, Washington, D.C. 20231.